Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Iocure Inc. is prosecuting a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This single action is being reviewed by 1 distinct examiner, PHAN, DOAN THI-THUC, in 1 distinct art unit. PHAN, DOAN THI-THUC is the busiest examiner with 1 busiest examiner pending. This concentration means the company's immediate patent prospects are in the hands of a single examiner. The involvement of 1 distinct art unit suggests a focused technological application.
For a portfolio with 1 pending office action, the prosecution strategy should be highly tailored to the 1 distinct examiner. Practitioners should note the high level of examiner concentration in this current snapshot. The absence of multiple examiner perspectives means there is no internal baseline for comparing examiner behavior. Every interaction with PHAN, DOAN THI-THUC is critical, as there are no other active matters to balance the portfolio's progress. This concentration means that the company's immediate patent prospects are shaped by a single individual's interpretation within the 1 distinct art unit. For a portfolio of this scale, the administrative overhead is minimal, but the strategic importance of the single examiner is high.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PHAN, DOAN THI-THUC | 1 | 42.8% | +47.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17821895 | IODINE COMPOUNDS FOR TREATING RESPIRATORY PATHOGENS | PHAN, DOAN THI-THUC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17821895 | IODINE COMPOUNDS FOR TREATING RESPIRATORY PATHOGENS | PHAN, DOAN THI-THUC | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17821895 | IODINE COMPOUNDS FOR TREATING RESPIRATORY PATHOGENS | PHAN, DOAN THI-THUC | 1613 | §103§112 | Non-Final OA | — | Pending | Aug 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIocure Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Doan Thi-Thuc Phan has the most, with 1 of Iocure Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
